GLP-1 receptor agonists (class)

MedicationExperimental6 reviews

-1.5

Average score out of 5

Based on 6 experience(s)

Experimental — This treatment is under research. Available data is limited. Consult your doctor before making any decision.

Class of medications used to treat type 2 diabetes and obesity. They are being studied for Long COVID due to their potential anti-inflammatory, neuroprotective and metabolic effects.

Information

Subcategory: Glucagon-like peptide-1 receptor agonist
Evidence level: 2/5
Evidence type: mechanistic rationale and trials in development
Treatment class: ✓

Score distribution

0 (0%)

1 (17%)

3 (50%)

Negative

2 (33%)

Practical information

Time to effect

< 1 week

Reported side effects

Induced the worst crash I’ve had in two years. Full brain fog (17%)PEM (17%)sensory/neurological issues (17%)muscle and bone pain/ache (17%)chronic fatigue (17%)

Latest reviews

Anonymous review-5

46-55 y.o. · 5/7/2026

Anonymous review0

26-35 y.o. · 5/5/2026

Has been helpful for weight loss but navigating side effects is a nightmare

Anonymous review-5

46-55 y.o. · 5/4/2026

Anonymous review+1

46-55 y.o. · 4/25/2026

Anonymous review0

65+ · 4/21/2026

Underweight: taking to treat long covid symptoms.

Share your experience

Your feedback helps thousands of people find what really works.

Join the community